VoICE Immunization Evidence
Neonatal invasive pneumococcal disease: New Zealand experience in the era of pneumococcal vaccination
Maternal immunization offers an opportunity to protect the mother and fetus, but also passes this protection on to the infant after birth.
Key Evidence: Despite the introduction of pneumococcal conjugate vaccine (PCV) in the childhood immunization program in New Zealand, the incidence of invasive pneumococcal disease in neonates (<30 days old) remains relatively high at 6 per 100,000 (versus 2/100,000 in the U.S.). Out of 19 cases in infants <30 days old in this study, 9 (47%) occurred during the first 7 days of life and 6 within the first 48 hours. If proven effective, maternal vaccination would cover 74% to 84% of the serotypes that infected these infants, depending on the vaccine.
Key Evidence: In a study of invasive pneumococcal disease in neonates in New Zealand following the introduction of pneumococcal conjugate vaccine (PCV) for infants, 67% of the cases in children <7 days old were of Maori ethnicity, while Maoris make up only 27% of New Zealand’s population. This over-representation of Maoris may be due to poverty and crowded living conditions and suggests that crowded households may be slower to experience the benefits of population-wide pneumococcal vaccination.
Mount V, Burton C, Jackson C, Heffernan H, Best E 2017. Neonatal invasive pneumococcal disease: New Zealand experience in the era of pneumococcal vaccination. Aust NZ J Obstet Gynaecol. 57 (3).